PHG vs POSC vs CBLL Stock Comparison

Koninklijke Philips, Positron and Ceribell Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (BFLY) Create a free account to keep reading and compare up to 10 companies.
PHG Koninklijke Philips Nv
$27.05 +7.7% 1M -0.9% 1Y
Market cap
$26.05B
P/E
13.9x
Revenue (TTM)
$20.60B
Div. yield
3.66%
Diagnostic Equipment Healthcare
4 wins
POSC Positron Corp
$1.72 -7.0% 1M +14.7% 1Y
Market cap
$56.50M
P/E
–
Revenue (TTM)
$462.27K
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
CBLL Ceribell, Inc.
$27.22 +11.1% 1M +112.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

8 decided of 12

Koninklijke Philips leads on 4 of the 12 questions below (Koninklijke Philips 4, Positron 3, Ceribell 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPHGPOSCCBLLLeader
Larger companyMarket capitalisation $26.05B $56.50M $1.04B PHG
Cheaper on earningsLower P/E, profitable companies only 13.9x -11.5x -15.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 13.7x — — –
Faster revenue growthRevenue growth, trailing twelve months +6.1% +202.2% +31.7% POSC
More profitableNet margin, trailing twelve months 8.9% -1,060.5% -64.7% PHG
Better return on capitalReturn on invested capital 11.5% — — –
Less leveragedLower net debt / EBITDA 1.8x -0.3x 1.6x POSC
Higher dividend yieldTrailing dividend yield 3.66% — — –
Better 1-year returnPrice return, last 12 months -0.9% +14.7% +112.2% CBLL
Better 5-year returnAnnualised price return, 5 years -10.6%/yr +23.5%/yr — POSC
Less volatileAnnualised volatility, 1 year 28.3% 86.7% 52.1% PHG
Higher overall scoreMean of the five percentile scores vs peers 80/100 13/100 39/100 PHG

Percentile Scorecard

PHGPOSCCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPHGPOSCCBLL
Valuation 98 #6 of 227 21 #179 of 227 24 #173 of 227
Growth 95 #11 of 219 19 #177 of 219 23 #170 of 219
Profitability 96 #9 of 205 4 #197 of 205 38 #128 of 205
Financial Health 31 #163 of 237 4 #227 of 237 81 #47 of 237
Shareholder Returns 79 #29 of 135 19 #110 of 135 28 #97 of 135
Overall 80 13 39
  • PHG ranked among 247 companies in Medical Devices and Diagnostics
  • POSC ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPHGPOSCCBLLSPY
1 month +7.7%-7.0%+11.1% +0.9%
3 months +3.6%+7.5%+53.5% +5.9%
6 months +5.7%-7.0%+41.4% +8.5%
Year to date -0.1%+3.0%+24.1% +13.3%
1 year -0.9%+14.7%+112.2% +12.4%
3 years +46.2%+37.6%— +88.1%
3 years, per year +13.5%+11.2%— +23.5%
5 years -42.8%+186.7%— +68.2%
5 years, per year -10.6%+23.5%— +11.0%
10 years -10.4%+5,633.3%— +263.4%
10 years, per year -1.1%+49.9%— +13.8%

Risk

MeasurePHGPOSCCBLLSPY
Volatility, 1Y 28.3%86.7%52.1% 12.7%
Downside volatility, 1Y 27.7%87.5%49.7% 12.7%
Beta vs S&P 500, 1Y 0.820.281.21 1.00
Return / volatility, 1Y -0.030.172.15 0.98
Max drawdown, 5Y -75.6%-65.6%-63.9% -25.4%
From 52-week high -17.8%-32.8%-1.7% -0.9%
52-week high $32.91$2.56$27.68 $779.14
52-week low $23.81$1.31$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePHGPOSCCBLL
P/E now vs peer median 13.9xmedian 28.8x -11.5xmedian 28.8x -15.7xmedian 28.8x
P/S now vs peer median 1.3xmedian 3.0x 122.2xmedian 3.0x 10.2xmedian 3.0x
EV/EBITDA now vs peer median 8.2xmedian 17.4x -12.2xmedian 17.4x -13.6xmedian 17.4x
P/FCF now vs peer median 6.0xmedian 25.7x -13.6xmedian 25.7x -19.0xmedian 25.7x
P/B now vs peer median 2.0xmedian 2.4x -85.5xmedian 2.4x 8.1xmedian 2.4x
PEG now vs peer median 0.33median 1.03 —median 1.03 —median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPHGPOSCCBLL
Revenue $20.60B $462.27K $101.96M
Gross profit $16.03B -$1.33M $90.65M
Operating income $2.65B -$4.82M -$69.97M
Net income $1.39B -$4.90M -$66.00M
Free cash flow $4.34B -$4.16M -$54.72M
R&D $2.00B – $22.95M
EPS (diluted) $1.91 $-0.15 $-1.74
Cash & equivalents $2.04B $357.17K $32.66M
Total debt $9.51B $2.00M $19.98M
Shares (diluted) 962.50M 32.85M 38.03M
Enterprise value $15.19B $49.22M $442.19M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPHGPOSCCBLL
P/E 13.9x -11.5x -15.7x
P/FCF 6.0x -13.6x -19.0x
P/Operating cash flow 9.8x -13.6x -19.3x
P/S 1.3x 122.2x 10.2x
P/B 2.0x -85.5x 8.1x
P/Tangible book 2.6x -85.5x 8.1x
EV/EBITDA 8.2x -12.2x -13.6x
EV/EBIT 12.6x -12.1x -13.3x
EV/Revenue 1.6x 125.8x 9.1x
EV/FCF 7.7x -14.0x -17.0x
EV/Operating cash flow 12.6x -14.0x -17.2x
PEG (3Y EPS CAGR) 0.33 – –

Growth

14 metrics
MetricPHGPOSCCBLL
Revenue growth (1Y) 6.1% 202.2% 31.7%
Revenue CAGR (3Y) 2.3% – –
Gross profit growth (1Y) 82.4% -15.2% 33.4%
Gross profit CAGR (3Y) 6.7% – –
Operating income growth (1Y) 121.3% -17.5% -34.6%
Operating income CAGR (3Y) 52.0% – –
Net income growth (1Y) 293.5% -18.0% -33.6%
Net income CAGR (3Y) 35.6% – –
EPS growth (1Y) 539.4% -12.5% -27.5%
EPS CAGR (3Y) 42.2% – –
Operating cash flow growth (1Y) 116.7% -17.0% -44.3%
Operating cash flow CAGR (3Y) 53.6% – –
Free cash flow growth (1Y) 54.2% -17.0% -41.8%
Free cash flow CAGR (3Y) 45.6% – –

Profitability

14 metrics
MetricPHGPOSCCBLL
Gross margin 77.8% -288.1% 88.9%
EBITDA margin 19.8% -1,030% -67.1%
Operating margin 12.9% -1,042% -68.6%
Pretax margin 11.9% -1,060% -64.7%
Net margin 8.9% -1,060% -64.7%
FCF margin 21.1% -900.4% -53.7%
Operating cash flow margin 12.9% -900.4% -53.0%
Return on equity 12.7% – -49.0%
Return on assets 5.4% -216.9% -38.3%
Return on invested capital 11.5% – –
Return on capital employed 11.8% -61,094% -45.1%
Asset turnover 0.7x 0.2x 0.6x
Cash conversion (OCF / net income) 1.9x 0.8x 0.8x
Stock comp / revenue 0.7% – 16.1%

Financial Health

11 metrics
MetricPHGPOSCCBLL
Debt / assets 31.2% 115.8% 12.0%
Debt / equity 0.7x -3.0x 0.2x
Net debt / EBITDA 1.8x -0.3x 1.6x
Debt / FCF 2.2x -0.5x -0.4x
Liabilities / assets 57.1% 138.2% 22.9%
Equity / assets 42.9% -38.2% 77.1%
Interest coverage 6.2x -43.8x -38.6x
Current ratio 1.3x 0.5x 9.2x
Quick ratio 0.7x 0.2x 8.6x
Cash ratio 0.2x 0.2x 7.5x
Altman Z-score – -114.72 14.47

Shareholder Returns

7 metrics
MetricPHGPOSCCBLL
Dividend yield 3.7% – –
Net buyback yield -0.5% -5.3% -0.6%
Shareholder yield 3.2% -5.3% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPHGPOSCCBLL
Forward P/E 13.7xFY2026 – –
EPS, next fiscal year $1.98FY2026 – $-1.86FY2026
EPS growth, next FY +6.5%FY2026 – –
EPS growth, the year after -10.1% – –
Revenue, next fiscal year $21.63BFY2026 – $118.32MFY2026
Revenue growth, next FY +1.8%FY2026 – +32.9%FY2026
Revenue growth, the year after -8.2% – +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPHGPOSCCBLL
Held by institutions 5.4% – 79.9%
Institutions holding 363 – 124
Change in shares held, QoQ +0.8% – +2.2%
Institutions buying 266 – 74
Institutions selling 76 – 36
Buyers to sellers 3.50 – 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PHGPOSCCBLL
PHG 1.00 0.02 0.23
POSC 0.02 1.00 0.03
CBLL 0.23 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PHG, POSC and CBLL?

Koninklijke Philips (PHG) is the largest by market capitalisation: Koninklijke Philips (PHG) $26.05B, Positron (POSC) $56.50M, Ceribell (CBLL) $1.04B.

Which company is growing faster?

Positron (POSC) grew revenue fastest over the trailing twelve months: Koninklijke Philips (PHG) +6.1%, Positron (POSC) +202.2%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Koninklijke Philips (PHG) 8.9%, Positron (POSC) -1,060.5%, Ceribell (CBLL) -64.7%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Koninklijke Philips (PHG) -0.9%, Positron (POSC) +14.7%, Ceribell (CBLL) +112.2%. Over five years, Positron (POSC) compounded fastest (Koninklijke Philips (PHG) -10.6%/yr, Positron (POSC) +23.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Koninklijke Philips (PHG) 3.66%. Positron (POSC) and Ceribell (CBLL) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Koninklijke Philips (PHG) 28.3%, Positron (POSC) 86.7%, Ceribell (CBLL) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PHG, POSC and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.